{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:54:02Z","timestamp":1791179642573,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.tracli.2007.04.002","type":"journal-article","created":{"date-parts":[[2007,5,12]],"date-time":"2007-05-12T07:13:19Z","timestamp":1178953999000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Fractionnement plasmatique international\u00a0: \u00e9tat des lieux"],"prefix":"10.1016","volume":"14","author":[{"given":"T.","family":"Burnouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2007.04.002_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/PPL-2006-00102","article-title":"Plasma proteins: Unique biopharmaceuticals - Unique economics","volume":"7","author":"Burnouf","year":"2006","journal-title":"Pharmaceuticals Policy and Law 2005"},{"key":"10.1016\/j.tracli.2007.04.002_bib2","unstructured":"WHO. Global data base on blood safety - Report 2001\u20132002- http:\/\/www.who.int\/bloodsafety\/GDBS_Report_2001\u20132002.pdf. Geneva: World Health Organization; 2004. 1\u201332 p."},{"key":"10.1016\/j.tracli.2007.04.002_bib3","unstructured":"WHO. Information sheet - Plasma Contract Fractionation Program wwwwhoint\/entity\/bloodproducts\/publications\/en\/Infosheet_plasma_contract_fractionationpdf."},{"key":"10.1016\/j.tracli.2007.04.002_bib4","unstructured":"Anonymous. Contract fractionation (rev. June 2004). Haemophilia. http:\/\/www.wfh.org. 2004."},{"key":"10.1016\/j.tracli.2007.04.002_bib5","unstructured":"WHO. Recommendations for the production, quality control and regulation of plasma for fractionation. http:\/\/www.who.int\/bloodproducts; 2005."},{"key":"10.1016\/j.tracli.2007.04.002_bib6","unstructured":"Anonymous. Human plasma for fractionation 01\/2007:0853 corrected. Strasbourg: European Pharmacopeia, Council of Europe, EDQM; 2007."},{"key":"10.1016\/j.tracli.2007.04.002_bib7","unstructured":"CHMP. Guideline on requirements for plasma master file (PMF) certification. CPMP\/BWP\/4663\/03. http:\/\/www.emea.eu.int; 2004."},{"key":"10.1016\/j.tracli.2007.04.002_bib8","unstructured":"CHMP. Guideline on the scientific data requirements for a plasma master file (PMF). EMEA\/CPMP\/BWP\/3794\/03. http:\/\/www.emea.eu.int: European Medicine Evaluation Agency; 2004."},{"key":"10.1016\/j.tracli.2007.04.002_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: Specific preventative strategies","volume":"14","author":"Burnouf","year":"2000","journal-title":"Blood Rev"},{"key":"10.1016\/j.tracli.2007.04.002_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1006\/biol.1999.0227","article-title":"Safety issues for plasma derivatives and benefit from NAT testing","volume":"27","author":"Willkommen","year":"1999","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2007.04.002_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","volume":"21","author":"Burnouf","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2007.04.002_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.tracli.2007.04.002_bib13","first-page":"414","article-title":"Large-scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier","volume":"7","author":"Kistler","year":"1962","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib14","first-page":"383","article-title":"Integration of chromatography with traditional plasma protein fractionation methods","volume":"1","author":"Burnouf","year":"1991","journal-title":"Bioseparation"},{"issue":"1","key":"10.1016\/j.tracli.2007.04.002_bib15","article-title":"Viruses and unconventional transmissible agents: Update on transmission via blood","volume":"7","author":"Barin","year":"2000","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2007.04.002_bib16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1046\/j.1537-2995.1999.39111160.x","article-title":"The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1","volume":"39","author":"Tabor","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.002_bib17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1537-2995.2003.00496.x","article-title":"West Nile virus and the safety of plasma derivatives: Verification of high safety margins, and the validity of predictions based on model virus data","volume":"43","author":"Kreil","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.002_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1423-0410.2004.00530.x","article-title":"Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products","volume":"87","author":"Remington","year":"2004","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib19","first-page":"101","article-title":"West Nile virus: Recent experience with the model virus approach","volume":"118","author":"Kreil","year":"2004","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.tracli.2007.04.002_bib20","unstructured":"CPMP. CPMP position statement on West Nile Virus and plasma-derived medicinal products. London: The european agency for the evaluation of medicinal products; 2003."},{"key":"10.1016\/j.tracli.2007.04.002_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1423-0410.2000.7810007.x","article-title":"Large-scale screening for human parvovirus B19 DNA by PCR: Application to the quality control of plasma for fractionation","volume":"78","author":"Aubin","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib22","unstructured":"CPMP. Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses (revised). CPMP\/BWP\/CPMP\/5136\/03. http:\/\/www.emea.eu.int. London: European agency for the evaluation of medicinal products (EMEA); 1996."},{"key":"10.1016\/j.tracli.2007.04.002_bib23","doi-asserted-by":"crossref","unstructured":"CPMP. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for proprietary medicinal products: Ad Hoc working party on biotechnology\/pharmacy and working party on safety medicines. http:\/\/www.emea.eu.int. Biologicals 1991; 19:247\u201351.","DOI":"10.1016\/1045-1056(91)90044-K"},{"key":"10.1016\/j.tracli.2007.04.002_bib24","unstructured":"CHMP. Guideline on assessing the risk for virus transmission - New chapter 6 of the note for guidance on plasma derived medicinal products (CPMP\/BWP\/269\/95) London: European medicines agency; 2004."},{"key":"10.1016\/j.tracli.2007.04.002_bib25","unstructured":"WHO. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. www.WHO.int. Geneva; 2003. 1\u201372 p."},{"key":"10.1016\/j.tracli.2007.04.002_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","article-title":"Inactivation of viruses in labile blood derivatives I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations","volume":"25","author":"Horowitz","year":"1985","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.002_bib27","first-page":"169","article-title":"Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation","volume":"81","author":"Nowak","year":"1993","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.tracli.2007.04.002_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/biol.2002.0332","article-title":"Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution","volume":"30","author":"Dichtelmuller","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2007.04.002_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1423-0410.2005.00731.x","article-title":"A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance","volume":"90","author":"Parkkinen","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/biol.2002.0334","article-title":"Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates","volume":"30","author":"Korneyeva","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2007.04.002_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1537-2995.1997.37597293884.x","article-title":"Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization","volume":"37","author":"Santagostino","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.002_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2003.00701.x","article-title":"Nanofiltration of plasma-derived biopharmaceutical products","volume":"9","author":"Burnouf","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2007.04.002_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/157341305774642894","article-title":"Place of nanofiltration for assuring viral safety of biologicals","volume":"1","author":"Burnouf","year":"2005","journal-title":"Current Nanoscience"},{"key":"10.1016\/j.tracli.2007.04.002_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1423-0410.2007.00892.x","article-title":"A solvent\/detergent-treated and 15-nm filtered factor VIII: A new safety standard for plasma derived coagulation factor concentrates","volume":"92","author":"Chtourou","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib35","first-page":"132","article-title":"Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates","volume":"67","author":"Burnouf-Radosevich","year":"1994","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.002_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1423-0410.2006.00833.x","article-title":"Creutzfeldt-Jakob disease and blood transfusion: Results of the UK transfusion medicine epidemiological review study","volume":"91","author":"Hewitt","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib38","unstructured":"Anonymous. Health protection agency. Fourth case of variant CJD associated with blood transfusion (press release). Press release, 18 January 2007. (http:\/\/www.hpa.org.uk\/hpa\/news\/articles\/press_releases\/2007\/070118_vCJD.htm). 2007."},{"key":"10.1016\/j.tracli.2007.04.002_bib39","unstructured":"WHO. WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies. http:\/\/www.who.int\/bloodproducts. 2006."},{"key":"10.1016\/j.tracli.2007.04.002_bib40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tracli.2006.11.001","article-title":"Current strategies to prevent transmission of prions by human plasma derivatives","volume":"13","author":"Burnouf","year":"2006","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2007.04.002_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.002_bib42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1751-2824.2006.00037.x","article-title":"Prion removal with filters","volume":"1","author":"Prowse","year":"2006","journal-title":"ISBT Science Series"},{"key":"10.1016\/j.tracli.2007.04.002_bib43","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.0041-1132.2003.00586.x","article-title":"Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy","volume":"43","author":"Cervenakova","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.002_bib44","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1537-2995.2006.00865.x","article-title":"Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands","volume":"46","author":"Gregori","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.002_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tmrv.2005.08.005","article-title":"Clearance of prions during plasma protein manufacture","volume":"20","author":"Burdick","year":"2006","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2007.04.002_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0042-9007.2004.00403.x","article-title":"Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII","volume":"86","author":"Foster","year":"2004","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0955-3886(00)00011-4","article-title":"Removal of abnormal prion protein by plasma fractionation","volume":"22","author":"Foster","year":"2000","journal-title":"Transfus Sci"},{"key":"10.1016\/j.tracli.2007.04.002_bib48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1423-0410.2000.7820086.x","article-title":"Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products","volume":"78","author":"Foster","year":"2000","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.tracli.2007.04.002_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1741-6892.2004.00444.x","article-title":"Removal of TSE agents from blood products","volume":"87","author":"Foster","year":"2004","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib50","first-page":"20","article-title":"Validation de l\u2019efficacit\u00e9 des \u00e9tapes de fractionnement du plasma dans l\u2019\u00e9limination des ATNC","volume":"13","author":"Flan","year":"2001","journal-title":"Sang Thrombose Vaisseaux"},{"key":"10.1016\/j.tracli.2007.04.002_bib51","series-title":"Evaluation of TSE removal procedures in the manufacture of plasma products","author":"Flan","year":"2005"},{"key":"10.1016\/j.tracli.2007.04.002_bib52","first-page":"8","article-title":"A highly purified factor VIII: C concentrate prepared from cryoprecipitate by ion-exchange chromatography","volume":"60","author":"Burnouf","year":"1991","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1423-0410.2006.00792.x","article-title":"Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process","volume":"91","author":"Furuya","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1423-0410.2006.00846.x","article-title":"A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process","volume":"92","author":"Teschner","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-3148.2001.00288.x","article-title":"Intravenous immunoglobulin: Regulatory perspectives on use and supply","volume":"11","author":"Farrugia","year":"2001","journal-title":"Transfus Med"},{"key":"10.1016\/j.tracli.2007.04.002_bib56","unstructured":"Application for the inclusion of polyvalent human immunoglobulins in the WHO model list of essential medicines. http:\/\/mednet3.who.int\/EML\/expcom\/expcom15\/applications\/immunoglobulin\/immunoSubmission.pdf. Geneva: WHO; 2007. 1\u201324 p."},{"issue":"4","key":"10.1016\/j.tracli.2007.04.002_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2516.2004.01007.x","article-title":"Product delivery in the developing world: Options, opportunities and threats","volume":"10","author":"Farrugia","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2007.04.002_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2516.1999.00317.x","article-title":"Haemophilia therapy: Assessing the cumulative risk of HIV exposure by cryoprecipitate","volume":"5","author":"Evatt","year":"1999","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2007.04.002_bib59","first-page":"1","article-title":"World federation of Hemophilia guide to developing a national patient registry. Montr\u00e9al","author":"Evatt","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2007.04.002_bib60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1423-0410.2006.00772.x","article-title":"A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system","volume":"91","author":"Burnouf","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib61","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1111\/j.1537-2995.2006.01035.x","article-title":"A process for solvent\/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system","volume":"46","author":"Burnouf","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.002_bib62","first-page":"53","article-title":"Tri (n-butyl) phosphate\/detergent treatment of licensed therapeutic and experimental blood derivatives","volume":"52","author":"Edwards","year":"1987","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.002_bib63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1246-7820(05)80044-8","article-title":"Viral safety of intravenous immunoglobulins G for therapeutic use","volume":"2","author":"Burnouf-Radosevich","year":"1995","journal-title":"Transfus Clin Biol"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782007000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782007000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:29:39Z","timestamp":1761128979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782007000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S1246782007000729"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2007.04.002","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fractionnement plasmatique international\u00a0: \u00e9tat des lieux","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2007.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}